Navigation Links
WaferGen to Present at the Rodman and Renshaw Annual Global Investment Conference
Date:9/3/2009

FREMONT, Calif., Sept. 3 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced that Mr. Alnoor Shivji, President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw Annual Global Investment Conference. The conference will be held September 9-11, 2009, at the New York Palace Hotel in New York.

Mr. Shivji's presentation will take place at 4:30 p.m. on Thursday, September 10th in the Fahnestock Salon. The presentation will include an overview of the company's SmartChip(TM) system, which has undergone successful alpha testing at The University of Pittsburg Medical Center (UPMC). As a result of the positive data, WaferGen has initiated multiple collaborations with academic research centers in the US and Europe. A live webcast of the presentation will be available at www.wafergen.com and will be archived for 90 days.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip(TM) is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets.

Forward-Looking Statements

This press release may contain certain "forward-looking statements". Such statements incl
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
3. WaferGen Announces Management Team Promotions
4. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
5. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
6. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
7. WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference
8. WaferGen Announces Signing of Two Private Placements
9. WaferGen to Present at the Ninth Annual Beyond Genome Conference
10. WaferGen Announces Second Quarter 2008 Financial Results
11. WaferGen to Present at the Seventh Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in ... association’s recent annual meeting drew praise from community leaders ... who called the action “a huge step forward … ... European innovation.” , The Board of Stakeholders voted to ... PPP at its 29 April meeting in Brussels, which ...
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... Sonia Moralejo Garca at the University of the Basque Country ... and other magnetic devices of wide industrial application. , It ... that are ever smaller and that nanotechnology, although it its ... in our society. Who has not heard of nanotubes, nanoparticles ...
... INCREASE 14.6%. Q4 2007 DILUTED EPS UP 20.8% TO $.64. 2008 ... $2.62 PER SHARE., ST. LOUIS, Feb. 12 , HIGHLIGHTS: ... -- Q4 2007 Sales Set New Quarterly Record: At $532.1 ... high, beating the Q2 2007 record of $507.5 ...
... of Dow AgroSciences Announces Milestone in Wall Street ... ,Dow AgroSciences LLC and Sangamo BioSciences, Inc. (Nasdaq: ... a key research milestone as part of,their joint ... successful application of Sangamo,s zinc finger DNA-binding,protein nuclease ...
Cached Biology Technology:A researcher of UPV/EHU has designed nanomagnets for industry 2Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 2Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 3Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 4Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 5Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 6Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 7Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 8Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 9Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 10Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 11Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 12Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 13Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 14Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 15Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 16Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 17Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 18Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 19Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark. 20Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 2Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 3Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration 4
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... Biology (SDB) 72nd Annual Meeting in Cancun, Mexico ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... shown a gene involved in neurodegenerative disease also plays ... circadian clock. , In a study of the ... Ataxin-2, keeps the clock responsible for sleeping and waking ... of the fruit fly,s sleep-wake cycle is disturbed, making ... fly. , The discovery is particularly interesting because ...
(Date:5/16/2013)... The relationship between the heritable risk for schizophrenia ... Schizophrenia is commonly associated with cognitive impairments that ... reduced IQ may be linked to the risk ... may precede the onset of schizophrenia symptoms. Also, ... of people diagnosed with schizophrenia. , In a ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Genetic risk for schizophrenia is connected to reduced IQ 2
... A new study, led by Felix Aigner, M.D., ... as potentially responsible for regulating the body's inflammatory ... complications involved with many transplantations is the damage ... following surgery, known as ischemia and reperfusion (IR). ...
... major role in deadly prion diseases by smashing up ... allow fatal brain illnesses to quickly spread, new Brown ... say, because they might reveal a way to control ... drug could be made that inhibits this fragmentation process, ...
... The costs due to complications from preterm birth are ... preterm infants are estimated to be almost $2 billion ... researchers found that giving nitroglycerin to mothers who had ... baby’s health. The results of the study are reported ...
Cached Biology News:Brown team finds crucial protein role in deadly prion spread 2
...
... to quantitate double-stranded DNA (dsDNA) in solution, even ... this kit, DNA is stained with Hoechst 33258 ... or other fluorometer. The kit quantitates dsDNA in ... 5 micrograms per ml and contains Hoechst 33258, ...
... of colony stimulating factors for assays of ... blood and fetal liver. Suitable for ... and CFU-GEMM when added to methylcellulose at ... of erythropoietin. Will also support growth ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
Biology Products: